INT169653

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 9
Disease Relevance 3.75
Pain Relevance 6.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Mgll) lipid metabolic process (Mgll)
Anatomy Link Frequency
forebrain 2
brain 1
Mgll (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 36 99.60 Very High Very High Very High
Endocannabinoid 103 99.50 Very High Very High Very High
Physical dependence 3 99.48 Very High Very High Very High
Inflammation 20 99.28 Very High Very High Very High
agonist 21 98.98 Very High Very High Very High
Cannabinoid receptor 38 98.78 Very High Very High Very High
Eae 10 98.60 Very High Very High Very High
tolerance 10 98.20 Very High Very High Very High
Analgesic 20 97.44 Very High Very High Very High
analgesia 7 95.56 Very High Very High Very High
Disease Link Frequency Relevance Heat
Sprains And Strains 56 99.72 Very High Very High Very High
Pain 30 99.60 Very High Very High Very High
Drug Dependence 3 99.48 Very High Very High Very High
INFLAMMATION 20 99.28 Very High Very High Very High
Neuropathic Pain 64 98.60 Very High Very High Very High
Obesity 4 97.76 Very High Very High Very High
Cognitive Disorder 2 94.84 High High
Hypothermia 6 94.40 High High
Appetite Loss 4 84.76 Quite High
Nociception 26 84.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We found that a similar form of functional antagonism was produced by sustained inactivation of monoacylglycerol lipase (MAGL), the principal degradative enzyme for the endocannabinoid 2-arachidonoylglycerol.
Negative_regulation (inactivation) of MAGL associated with endocannabinoid
1) Confidence 0.42 Published 2010 Journal Nat. Neurosci. Section Abstract Doc Link 20729846 Disease Relevance 0.07 Pain Relevance 0.66
After repeated administration, the MAGL inhibitor JZL184 lost its analgesic activity and produced cross-tolerance to cannabinoid receptor (CB1) agonists in mice, effects that were phenocopied by genetic disruption of Mgll (encoding MAGL).
Negative_regulation (disruption) of Mgll associated with cannabinoid receptor, analgesic, agonist and tolerance
2) Confidence 0.41 Published 2010 Journal Nat. Neurosci. Section Abstract Doc Link 20729846 Disease Relevance 0.10 Pain Relevance 0.96
Chronic MAGL blockade also caused physical dependence, impaired endocannabinoid-dependent synaptic plasticity and desensitized brain CB1 receptors.
Negative_regulation (blockade) of MAGL in brain associated with endocannabinoid, cannabinoid receptor and physical dependence
3) Confidence 0.37 Published 2010 Journal Nat. Neurosci. Section Abstract Doc Link 20729846 Disease Relevance 0.10 Pain Relevance 0.96
However, it has been shown that inhibition of endocannabinoid metabolism via specific inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL) reduces pain in inflammatory and neuropathic pain models [11], [12], without producing diverse side effects, such as temporary memory impairment, addiction and psychotropic effects, which are associated with agonists at cannabinoid-1 (CB1) receptors in forebrain circuits.
Negative_regulation (inhibition) of monoacylglycerol lipase in forebrain associated with addiction, pain, endocannabinoid, cognitive disorder, inflammation, cannabinoid, eae and agonist
4) Confidence 0.28 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2869361 Disease Relevance 1.26 Pain Relevance 1.22
However, it has been shown that inhibition of endocannabinoid metabolism via specific inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL) reduces pain in inflammatory and neuropathic pain models [11], [12], without producing diverse side effects, such as temporary memory impairment, addiction and psychotropic effects, which are associated with agonists at cannabinoid-1 (CB1) receptors in forebrain circuits.
Negative_regulation (inhibition) of MAGL in forebrain associated with addiction, pain, endocannabinoid, cognitive disorder, inflammation, cannabinoid, eae and agonist
5) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2869361 Disease Relevance 1.26 Pain Relevance 1.22
Indeed, inhibition of MGL using a specific inhibitor in mice raised 2-AG levels and induced cannabinoid receptor-dependent effects like analgesia, hypomotility, and hypothermia [9].
Negative_regulation (inhibition) of MGL associated with hypothermia, cannabinoid receptor and analgesia
6) Confidence 0.13 Published 2010 Journal Biochimica et Biophysica Acta Section Body Doc Link PMC2911655 Disease Relevance 0.33 Pain Relevance 0.58
Thus, inhibiting 2-AG hydrolyzing enzymes, such as MGL, is considered a promising pharmacological approach to modulate EC levels [8].
Negative_regulation (inhibiting) of MGL associated with endocannabinoid
7) Confidence 0.09 Published 2010 Journal Biochimica et Biophysica Acta Section Body Doc Link PMC2911655 Disease Relevance 0.34 Pain Relevance 0.57
Currently, a mouse model lacking MGL does not exist.
Negative_regulation (lacking) of MGL
8) Confidence 0.09 Published 2010 Journal Biochimica et Biophysica Acta Section Body Doc Link PMC2911655 Disease Relevance 0.10 Pain Relevance 0
lacks detectable MGL activity at pH 7.5 against rac-1(3)-OG, and hydrolysis of 2-OG was reduced by ? 
Negative_regulation (lacks) of MGL
9) Confidence 0.09 Published 2010 Journal Biochimica et Biophysica Acta Section Body Doc Link PMC2911655 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox